It's the first drug shown to slow Alzheimer's. Why is is it off to a slow start?
Time:2024-05-21 15:54:02 Source:travelViews(143)
The first drug shown to slow Alzheimer’s disease hit the U.S. market over a year ago, but sales have lagged, major hospital systems have taken months to start using it and some insurers have rejected coverage.
Doctors also expect some patients will hesitate to take Leqembi due to its limited impact and potential side effects. They say it will take years to learn how best to deploy the drug and that work must be done to improve diagnosis.
“This is the start of a very exciting journey,” said Dr. Ambar Kulshreshtha, a suburban Atlanta family physician focused on dementia patients.
More than 6 million Americans, and millions more worldwide, have Alzheimer’s disease, the most common cause of dementia. There’s no cure, but Leqembi clears a sticky brain protein called amyloid that’s a key indicator of Alzheimer’s.
Studies showed that it can delay the progression of the disease by a few months when given to people with mild symptoms. Some experts say the delay may be too subtle for patients to notice.
Previous:Trump accepts a VP debate but wants it on Fox News. Harris has already said yes to CBS
Next:Adams, Reyna, Turner, Ream are US concerns ahead of Copa America
You may also like
- Cruise worker 'murders newborn son on board ship': Shocked co
- Breakthrough laryngeal allotransplantation offers hope to patients in China
- Resolving border issue 'in common interest' of China and India: Chinese FM
- ASEAN voices opposition to taking sides
- Inquiry slams UK authorities for failures that killed thousands in infected blood scandal
- Curb on Chinese talent sparks strong backlash
- Washington manipulates freedom of speech, report finds
- China conducts in
- US overdose deaths dropped in 2023, the first time since 2018